{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:54:26Z","timestamp":1787698466878,"version":"build-2784847793"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s11523-025-01151-7","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T10:26:33Z","timestamp":1748255193000},"page":"597-613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4957-8298","authenticated-orcid":false,"given":"Phillip H.","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"11","key":"1151_CR1","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180\u201392.","journal-title":"Int J Clin Pract"},{"key":"1151_CR2","unstructured":"National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) for prostate cancer V.1.2025. 2025. Accessed 25 Mar 2025."},{"issue":"1160","key":"1151_CR3","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/bjr\/tqae092","volume":"97","author":"M Naik","year":"2024","unstructured":"Naik M, Khan SR, Lewington V, Challapalli A, Eccles A, Barwick TD. Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands. Br J Radiol. 2024;97(1160):1391\u2013404.","journal-title":"Br J Radiol"},{"key":"1151_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.euros.2022.05.007","volume":"41","author":"C Stenman","year":"2022","unstructured":"Stenman C, Abrahamsson E, Reds\u00e4ter M, Gnanapragasam VJ, Bratt O. Rates of positive abdominal computed tomography and bone scan findings among men with Cambridge Prognostic Group 4 or 5 prostate cancer: a nationwide registry study. Eur Urol Open Sci. 2022;41:123\u20135.","journal-title":"Eur Urol Open Sci."},{"issue":"4","key":"1151_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76(4):469\u201378.","journal-title":"Eur Urol"},{"key":"1151_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.630589","volume":"11","author":"PJ Vlachostergios","year":"2021","unstructured":"Vlachostergios PJ, Niaz MJ, Sun M, et al. Prostate-specific membrane antigen uptake and survival in metastatic castration-resistant prostate cancer. Front Oncol. 2021;11: 630589.","journal-title":"Front Oncol"},{"key":"1151_CR7","doi-asserted-by":"publisher","first-page":"175883592312089","DOI":"10.1177\/17588359231208960","volume":"15","author":"A Georgakopoulos","year":"2023","unstructured":"Georgakopoulos A, Bamias A, Chatziioannou S. Current role of PSMA-PET imaging in the clinical management of prostate cancer. Ther Adv Med Oncol. 2023;15:17588359231208960.","journal-title":"Ther Adv Med Oncol."},{"key":"1151_CR8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3389\/fonc.2018.00623","volume":"8","author":"MC Hupe","year":"2018","unstructured":"Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:623.","journal-title":"Front Oncol"},{"issue":"5","key":"1151_CR9","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48(5):1626\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1151_CR10","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/modpathol.2008.143","volume":"21","author":"IO Gordon","year":"2008","unstructured":"Gordon IO, Tretiakova MS, Noffsinger AE, Hart J, Reuter VE, Al-Ahmadie HA. Prostate-specific membrane antigen expression in regeneration and repair. Mod Pathol. 2008;21(12):1421\u20137.","journal-title":"Mod Pathol"},{"issue":"3","key":"1151_CR11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.2967\/jnumed.112.111203","volume":"54","author":"JA Barrett","year":"2013","unstructured":"Barrett JA, Coleman RE, Goldsmith SJ, et al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013;54(3):380\u20137.","journal-title":"J Nucl Med"},{"issue":"5","key":"1151_CR12","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl. 1","key":"1151_CR13","first-page":"1","volume":"7","author":"S Sarkar","year":"2016","unstructured":"Sarkar S, Das S. A review of imaging methods for prostate cancer detection. Biomed Eng Comput Biol. 2016;7(Suppl. 1):1\u201315.","journal-title":"Biomed Eng Comput Biol."},{"issue":"1","key":"1151_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.semnuclmed.2023.07.001","volume":"54","author":"MR Jochumsen","year":"2024","unstructured":"Jochumsen MR, Bouchelouche K. PSMA PET\/CT for primary staging of prostate cancer: an updated overview. Semin Nucl Med. 2024;54(1):39\u201345.","journal-title":"Semin Nucl Med"},{"key":"1151_CR15","unstructured":"Novartis Pharmaceuticals Corporation. Locametz: prescribing information. 2022."},{"issue":"6","key":"1151_CR16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.euo.2018.11.007","volume":"2","author":"SP Thang","year":"2019","unstructured":"Thang SP, Violet J, Sandhu S, et al. Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for (177)Lu-labelled PSMA radioligand therapy. Eur Urol Oncol. 2019;2(6):670\u20136.","journal-title":"Eur Urol Oncol."},{"key":"1151_CR17","unstructured":"Novartis Pharmaceuticals Corporation. Pluvicto\u2122 (lutetium Lu-177 vipivotide tetraxetan) injection, for intravenous use [prescribing information]. 2022. Last updated March 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215833s021s024lbl.pdf. Accessed Apr 2025."},{"issue":"13","key":"1151_CR18","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","volume":"27","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of (18)F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27(13):3674\u201382.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1151_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206(1):52\u201361.","journal-title":"J Urol"},{"issue":"2","key":"1151_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/JU.0000000000003493","volume":"210","author":"AB Jani","year":"2023","unstructured":"Jani AB, Ravizzini GC, Gartrell BA, et al. Diagnostic performance and safety of (18)F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT). J Urol. 2023;210(2):299\u2013311.","journal-title":"J Urol"},{"issue":"4","key":"1151_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","volume":"84","author":"DS Surasi","year":"2023","unstructured":"Surasi DS, Eiber M, Maurer T, et al. Diagnostic performance and safety of positron emission tomography with (18)F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE). Eur Urol. 2023;84(4):361\u201370.","journal-title":"Eur Urol"},{"issue":"6","key":"1151_CR22","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856\u201363.","journal-title":"JAMA Oncol"},{"issue":"11","key":"1151_CR23","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021;7(11):1635\u201342.","journal-title":"JAMA Oncol"},{"issue":"19","key":"1151_CR24","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.3390\/cancers15194839","volume":"15","author":"W Echavidre","year":"2023","unstructured":"Echavidre W, Fagret D, Faraggi M, Picco V, Montemagno C. Recent pre-clinical advancements in nuclear medicine: pioneering the path to a limitless future. Cancers (Basel). 2023;15(19):4839.","journal-title":"Cancers (Basel)."},{"issue":"4","key":"1151_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2967\/jnumed.122.264743","volume":"64","author":"P Olivier","year":"2023","unstructured":"Olivier P, Giraudet AL, Skanjeti A, et al. Phase III study of (18)F-PSMA-1007 versus (18)F-fluorocholine PET\/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, crossover multicenter study. J Nucl Med. 2023;64(4):579\u201385.","journal-title":"J Nucl Med"},{"key":"1151_CR26","unstructured":"(ANSM) Andsdmedpds. Protocole D\u2019utilisation therapeutique et de Recueil D\u2019informations ABX-PSMA-1007, 1300 MBq\/mL solution injectable, substance active: [18F]PSMA-1007. 2010. 2024. Available from: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/extrait.php?specid=64034289. Accessed Mar 2025."},{"issue":"4","key":"1151_CR27","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","volume":"27","author":"S Huang","year":"2023","unstructured":"Huang S, Ong S, McKenzie D, et al. Comparison of (18)F-based PSMA radiotracers with [(68)Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;27(4):654\u201364.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"1151_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/diagnostics13010158","volume":"13","author":"A Adnan","year":"2023","unstructured":"Adnan A, Basu S. PSMA receptor-based PET-CT: the basics and current status in clinical and research applications. Diagnostics (Basel). 2023;13(1):158.","journal-title":"Diagnostics (Basel)."},{"issue":"12","key":"1151_CR29","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","volume":"51","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D, et al. The homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging. 2024;51(12):3753\u201364.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1151_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40336-024-00631-6","volume":"12","author":"S Woo","year":"2024","unstructured":"Woo S, Freedman D, Becker AS, et al. Equivocal bone lesions on PSMA PET\/CT: systematic review and meta-analysis on their prevalence and malignancy rate. Clin Transl Imaging. 2024;12(5):485\u2013500.","journal-title":"Clin Transl Imaging."},{"issue":"13","key":"1151_CR31","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","volume":"48","author":"H Grunig","year":"2021","unstructured":"Grunig H, Maurer A, Thali Y, et al. Focal unspecific bone uptake on [(18)F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2021;48(13):4483\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1151_CR32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13550-023-01033-x","volume":"13","author":"J Heilinger","year":"2023","unstructured":"Heilinger J, Weindler J, Roth KS, et al. Threshold for defining PSMA-positivity prior to (177)Lu-PSMA therapy: a comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]F-DCFPyL in metastatic prostate cancer. EJNMMI Res. 2023;13(1):83.","journal-title":"EJNMMI Res"},{"issue":"8","key":"1151_CR33","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.2967\/jnumed.120.251447","volume":"62","author":"M Kroenke","year":"2021","unstructured":"Kroenke M, Mirzoyan L, Horn T, et al. Matched-pair comparison of (68)Ga-PSMA-11 and (18)F-rhPSMA-7 PET\/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor-related uptake and tumor positivity. J Nucl Med. 2021;62(8):1082\u20138.","journal-title":"J Nucl Med"},{"issue":"4","key":"1151_CR34","doi-asserted-by":"publisher","first-page":"540","DOI":"10.2967\/jnumed.123.267042","volume":"65","author":"TA Hope","year":"2024","unstructured":"Hope TA, Jadvar H. PSMA PET AUC updates: inclusion of rh-PSMA-7.3. J Nucl Med. 2024;65(4):540.","journal-title":"J Nucl Med"},{"issue":"1","key":"1151_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","volume":"19","author":"G Ferreira","year":"2019","unstructured":"Ferreira G, Iravani A, Hofman MS, Hicks RJ. Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution. Cancer Imaging. 2019;19(1):23.","journal-title":"Cancer Imaging"},{"issue":"3","key":"1151_CR36","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1200\/OP.22.00753","volume":"19","author":"R Garje","year":"2023","unstructured":"Garje R, Hope TA, Rumble RB, Parikh RA. Systemic therapy update on (177)lutetium-PSMA-617 for metastatic castration-resistant prostate cancer: ASCO guideline rapid recommendation Q and A. JCO Oncol Pract. 2023;19(3):132\u20135.","journal-title":"JCO Oncol Pract."},{"issue":"Suppl. 1","key":"1151_CR37","doi-asserted-by":"publisher","first-page":"e586s","DOI":"10.6061\/clinics\/2018\/e586s","volume":"73","author":"FG Barbosa","year":"2018","unstructured":"Barbosa FG, Queiroz MA, Nunes RF, Marin JFG, Buchpiguel CA, Cerri GG. Clinical perspectives of PSMA PET\/MRI for prostate cancer. Clinics (Sao Paulo). 2018;73(Suppl. 1):e586s.","journal-title":"Clinics (Sao Paulo)"},{"issue":"12","key":"1151_CR38","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1007\/s00261-023-04002-z","volume":"48","author":"S Houshmand","year":"2023","unstructured":"Houshmand S, Lawhn-Heath C, Behr S. PSMA PET imaging in the diagnosis and management of prostate cancer. Abdom Radiol (NY). 2023;48(12):3610\u201323.","journal-title":"Abdom Radiol (NY)."},{"key":"1151_CR39","doi-asserted-by":"publisher","first-page":"175883591987682","DOI":"10.1177\/1758835919876828","volume":"11","author":"R Alipour","year":"2019","unstructured":"Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol. 2019;11:1758835919876828.","journal-title":"Ther Adv Med Oncol."},{"issue":"1","key":"1151_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2967\/jnumed.121.263262","volume":"63","author":"H Jadvar","year":"2022","unstructured":"Jadvar H, Calais J, Fanti S, et al. Appropriate use criteria for prostate-specific membrane antigen PET imaging. J Nucl Med. 2022;63(1):59\u201368.","journal-title":"J Nucl Med"},{"issue":"5","key":"1151_CR41","first-page":"14N","volume":"63","author":"TA Hope","year":"2022","unstructured":"Hope TA, Jadvar H. Updates to appropriate use criteria for PSMA PET. J Nucl Med. 2022;63(5):14N.","journal-title":"J Nucl Med"},{"issue":"24","key":"1151_CR42","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","volume":"25","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Weber M, Iravani A, et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25(24):7448\u201354.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1151_CR43","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.eururo.2024.01.019","volume":"85","author":"M Weber","year":"2024","unstructured":"Weber M, Fendler WP, Ravi Kumar AS, et al. Prostate-specific membrane antigen positron emission tomography-detected disease extent and overall survival of patients with high-risk nonmetastatic castration-resistant prostate cancer: an international multicenter retrospective study. Eur Urol. 2024;85(6):511\u20136.","journal-title":"Eur Urol"},{"issue":"9","key":"1151_CR44","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","volume":"25","author":"MJ Karpinski","year":"2024","unstructured":"Karpinski MJ, H\u00fcsing J, Claassen K, et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol. 2024;25(9):1188\u2013201.","journal-title":"Lancet Oncol"},{"issue":"10276","key":"1151_CR45","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"M Hofman","year":"2021","unstructured":"Hofman M, Emmett L, Sandhu S, et al. 177Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804.","journal-title":"Lancet"},{"issue":"12","key":"1151_CR46","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10459","key":"1151_CR47","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227\u201339.","journal-title":"Lancet"},{"key":"1151_CR48","doi-asserted-by":"publisher","first-page":"1483953","DOI":"10.3389\/fonc.2024.1483953","volume":"14","author":"AR Hansen","year":"2024","unstructured":"Hansen AR, Probst S, Beauregard JM, et al. Initial clinical experience with [(177)Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial. Front Oncol. 2024;14:1483953.","journal-title":"Front Oncol"},{"issue":"16","key":"1151_CR49","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.3390\/cancers13164134","volume":"13","author":"F Khreish","year":"2021","unstructured":"Khreish F, Ribbat K, Bartholom\u00e4 M, et al. Value of combined PET imaging with [(18)F]FDG and [(68)Ga]Ga-PSMA-11 in mCRPC patients with worsening disease during [(177)Lu]Lu-PSMA-617 RLT. Cancers (Basel). 2021;13(16):4134.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1151_CR50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25(1):99\u2013107.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1151_CR51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12149-023-01874-5","volume":"38","author":"K Michalski","year":"2024","unstructured":"Michalski K, Kosmala A, Werner RA, et al. Comparison of PET\/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy. Ann Nucl Med. 2024;38(2):87\u201395.","journal-title":"Ann Nucl Med"},{"key":"1151_CR52","unstructured":"ClinicalTrials.gov. Study evaluating mCRPC treatment using PSMA [Lu-177]-PNT2002 therapy after second-line hormonal treatment (SPLASH). NCT04647526. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04647526?cond=NCT04647526&rank=1. Accessed Mar 2025."},{"issue":"9","key":"1151_CR53","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.2967\/jnumed.123.265952","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope TA, Antonarakis ES, Bodei L, et al. SNMMI consensus statement on patient selection and appropriate use of 177Lu-PSMA-617 radionuclide therapy. J Nucl Med. 2023;64(9):1417\u201323.","journal-title":"J Nucl Med"},{"issue":"6","key":"1151_CR54","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2967\/jnumed.121.263638","volume":"63","author":"PH Kuo","year":"2022","unstructured":"Kuo PH, Benson T, Messmann R, Groaning M. Why we did what we did: PSMA PET\/CT selection criteria for the VISION Trial. J Nucl Med. 2022;63(6):816\u20138.","journal-title":"J Nucl Med"},{"issue":"2","key":"1151_CR55","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1151_CR56","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2967\/jnumed.123.266391","volume":"65","author":"A Farolfi","year":"2024","unstructured":"Farolfi A, Armstrong WR, Djaileb L, et al. Differences and common ground in (177)Lu-PSMA radioligand therapy practice patterns: international survey of 95 theranostic centers. J Nucl Med. 2024;65(3):438\u201345.","journal-title":"J Nucl Med"},{"issue":"11","key":"1151_CR57","first-page":"1644","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J, et al. The PRIMARY score: using intraprostatic (68)Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis. J Nucl Med. 2022;63(11):1644\u201350.","journal-title":"J Nucl Med"},{"issue":"4","key":"1151_CR58","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","volume":"73","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies. Eur Urol. 2018;73(4):485\u20137.","journal-title":"Eur Urol"},{"issue":"3","key":"1151_CR59","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59(3):469\u201378.","journal-title":"J Nucl Med"},{"issue":"1","key":"1151_CR60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2967\/jnumed.119.229187","volume":"61","author":"I Rauscher","year":"2020","unstructured":"Rauscher I, Kronke M, Konig M, et al. Matched-pair comparison of (68)Ga-PSMA-11 PET\/CT and (18)F-PSMA-1007 PET\/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2020;61(1):51\u20137.","journal-title":"J Nucl Med"},{"issue":"5","key":"1151_CR61","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2967\/jnumed.118.215434","volume":"64","author":"R Seifert","year":"2023","unstructured":"Seifert R, Telli T, Opitz M, et al. Unspecific (18)F-PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scanning, and MRI triple validation in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2023;64(5):738\u201343.","journal-title":"J Nucl Med"},{"issue":"13","key":"1151_CR62","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00259-021-05456-3","volume":"48","author":"EG Arnfield","year":"2021","unstructured":"Arnfield EG, Thomas PA, Roberts MJ, et al. Clinical insignificance of [(18)F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. Eur J Nucl Med Mol Imaging. 2021;48(13):4495\u2013507.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1151_CR63","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13550-021-00845-z","volume":"11","author":"S Hoberuck","year":"2021","unstructured":"Hoberuck S, Lock S, Borkowetz A, et al. Intraindividual comparison of [(68) Ga]-Ga-PSMA-11 and [(18)F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Res. 2021;11(1):109.","journal-title":"EJNMMI Res"},{"issue":"1","key":"1151_CR64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13550-023-00981-8","volume":"13","author":"AH Dias","year":"2023","unstructured":"Dias AH, Jochumsen MR, Zacho HD, Munk OL, Gormsen LC. Multiparametric dynamic whole-body PSMA PET\/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007. EJNMMI Res. 2023;13(1):31.","journal-title":"EJNMMI Res"},{"issue":"6","key":"1151_CR65","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1053\/j.semnuclmed.2021.06.016","volume":"51","author":"R Mei","year":"2021","unstructured":"Mei R, Farolfi A, Castellucci P, Nanni C, Zanoni L, Fanti S. PET\/CT variants and pitfalls in prostate cancer: what you might see on PET and should never forget. Semin Nucl Med. 2021;51(6):621\u201332.","journal-title":"Semin Nucl Med"},{"issue":"3","key":"1151_CR66","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00259-019-04552-9","volume":"47","author":"I Alberts","year":"2020","unstructured":"Alberts I, Sachpekidis C, Dijkstra L, et al. The role of additional late PSMA-ligand PET\/CT in the differentiation between lymph node metastases and ganglia. Eur J Nucl Med Mol Imaging. 2020;47(3):642\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1151_CR67","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/j.semnuclmed.2019.02.006","volume":"49","author":"S Sheikhbahaei","year":"2019","unstructured":"Sheikhbahaei S, Werner RA, Solnes LB, et al. Prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer: an update on important pitfalls. Semin Nucl Med. 2019;49(4):255\u201370.","journal-title":"Semin Nucl Med"},{"issue":"5","key":"1151_CR68","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2967\/jnumed.122.264741","volume":"64","author":"R Seifert","year":"2023","unstructured":"Seifert R, Telli T, Hadaschik B, Fendler WP, Kuo PH, Herrmann K. Is (18)F-FDG PET needed to assess (177)Lu-PSMA therapy eligibility? A VISION-like, single-center analysis. J Nucl Med. 2023;64(5):731\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"1151_CR69","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00259-024-06857-w","volume":"52","author":"SA Esfahani","year":"2024","unstructured":"Esfahani SA, Morris MJ, Sartor O, et al. Standardized template for clinical reporting of PSMA PET\/CT scans. Eur J Nucl Med Mol Imaging. 2024;52(1):335\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1151_CR70","doi-asserted-by":"publisher","first-page":"678","DOI":"10.2967\/jnumed.119.233817","volume":"61","author":"S Fanti","year":"2020","unstructured":"Fanti S, Hadaschik B, Herrmann K. Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria. J Nucl Med. 2020;61(5):678\u201382.","journal-title":"J Nucl Med"},{"issue":"11","key":"1151_CR71","first-page":"1651","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M, et al. Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63(11):1651\u20138.","journal-title":"J Nucl Med"},{"issue":"1","key":"1151_CR72","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222148","volume":"308","author":"A Gafita","year":"2023","unstructured":"Gafita A, Djaileb L, Rauscher I, et al. Response Evaluation Criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer. Radiology. 2023;308(1): e222148.","journal-title":"Radiology"},{"issue":"6","key":"1151_CR73","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2967\/jnumed.123.267234","volume":"65","author":"A Gafita","year":"2024","unstructured":"Gafita A, Djaileb L, Rauscher I, et al. RECIP 1.0 predicts progression-free survival after [(177)Lu]Lu-PSMA radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2024;65(6):917\u201322.","journal-title":"J Nucl Med"},{"issue":"11","key":"1151_CR74","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.2967\/jnumed.122.265155","volume":"64","author":"V Murthy","year":"2023","unstructured":"Murthy V, Gafita A, Thin P, et al. Prognostic value of end-of-treatment PSMA PET\/CT in patients treated with (177)Lu-PSMA radioligand therapy: a retrospective, single-center analysis. J Nucl Med. 2023;64(11):1737\u201343.","journal-title":"J Nucl Med"},{"key":"1151_CR75","doi-asserted-by":"publisher","first-page":"S970","DOI":"10.1016\/j.annonc.2024.08.1689","volume":"35","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Gafita A, Bressel M, et al. 1608P Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET\/CT for response evaluation: analysis from the PRINCE trial. Ann Oncol. 2024;35:S970.","journal-title":"Ann Oncol"},{"key":"1151_CR76","unstructured":"ClinicalTrials.gov. PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (PRINCE). NCT03658447. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03658447. Accessed Mar 2025."},{"issue":"1","key":"1151_CR77","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2174\/1874471008666150313114644","volume":"9","author":"T Das","year":"2016","unstructured":"Das T, Banerjee S. Theranostic applications of lutetium-177 in radionuclide therapy. Curr Radiopharm. 2016;9(1):94\u2013101.","journal-title":"Curr Radiopharm"},{"issue":"12","key":"1151_CR78","first-page":"1851","volume":"65","author":"H Jadvar","year":"2024","unstructured":"Jadvar H, Iravani A, Bodei L, Calais J. Challenges with (177)Lu-PSMA-617 radiopharmaceutical therapy in clinical practice. J Nucl Med. 2024;65(12):1851\u20134.","journal-title":"J Nucl Med"},{"issue":"3","key":"1151_CR79","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2967\/jnumed.124.268325","volume":"66","author":"L Emmett","year":"2025","unstructured":"Emmett L. SPECT deserves RESPECT: the potential of SPECT\/CT to optimize patient outcomes with theranostics therapy. J Nucl Med. 2025;66(3):349\u201350.","journal-title":"J Nucl Med"},{"issue":"3","key":"1151_CR80","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2967\/jnumed.122.264677","volume":"64","author":"N John","year":"2023","unstructured":"John N, Pathmanandavel S, Crumbaker M, et al. (177)Lu-PSMA SPECT quantitation at 6 weeks (dose 2) predicts short progression-free survival for patients undergoing (177)Lu-PSMA-I&T therapy. J Nucl Med. 2023;64(3):410\u20135.","journal-title":"J Nucl Med"},{"issue":"2","key":"1151_CR81","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2967\/jnumed.122.264398","volume":"64","author":"S Pathmanandavel","year":"2023","unstructured":"Pathmanandavel S, Crumbaker M, Ho B, et al. Evaluation of (177)Lu-PSMA-617 SPECT\/CT quantitation as a response biomarker within a prospective (177)Lu-PSMA-617 and NOX66 combination trial (LuPIN). J Nucl Med. 2023;64(2):221\u20136.","journal-title":"J Nucl Med"},{"key":"1151_CR82","doi-asserted-by":"publisher","first-page":"175883592311563","DOI":"10.1177\/17588359231156392","volume":"15","author":"L Emmett","year":"2023","unstructured":"Emmett L, John N, Pathmanandavel S, et al. Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). Ther Adv Med Oncol. 2023;15:17588359231156392.","journal-title":"Ther Adv Med Oncol."},{"issue":"9","key":"1151_CR83","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s00259-024-06718-6","volume":"51","author":"H Song","year":"2024","unstructured":"Song H, Leonio MI, Ferri V, et al. Same-day post-therapy imaging with a new generation whole-body digital SPECT\/CT in assessing treatment response to [(177)Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2024;51(9):2784\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1151_CR84","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2967\/jnumed.122.264677","volume":"64","author":"N John","year":"2023","unstructured":"John N, Pathmanandavel S, Crumbaker M, et al. 177Lu-PSMA SPECT quantitation at 6 weeks (dose 2) predicts short progression-free survival for patients undergoing 177Lu-PSMA-I&T therapy. J Nucl Med. 2023;64(3):410\u20135.","journal-title":"J Nucl Med"},{"key":"1151_CR85","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-med-081522-031439","volume":"75","author":"LM Unterrainer","year":"2024","unstructured":"Unterrainer LM, Calais J, Bander NH. Prostate-specific membrane antigen: gateway to management of advanced prostate cancer. Annu Rev Med. 2024;75:49\u201366.","journal-title":"Annu Rev Med"},{"issue":"12","key":"1151_CR86","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2967\/jnumed.123.265874","volume":"64","author":"QA Shagera","year":"2023","unstructured":"Shagera QA, Karfis I, Kristanto P, et al. PSMA PET\/CT for response assessment and overall survival prediction in patients with metastatic castration-resistant prostate cancer treated with androgen receptor pathway Iihibitors. J Nucl Med. 2023;64(12):1869\u201375.","journal-title":"J Nucl Med"},{"issue":"6","key":"1151_CR87","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","volume":"48","author":"K Michalski","year":"2021","unstructured":"Michalski K, Ruf J, Goetz C, et al. Prognostic implications of dual tracer PET\/CT: PSMA ligand and [(18)F]FDG PET\/CT in patients undergoing [(177)Lu]PSMA radioligand therapy. Eur J Nucl Med Mol Imaging. 2021;48(6):2024\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1151_CR88","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2967\/jnumed.119.231431","volume":"61","author":"H Rathke","year":"2020","unstructured":"Rathke H, Holland-Letz T, Mier W, et al. Response prediction of (177)Lu-PSMA-617 radioligand therapy using prostate-specific antigen, chromogranin A, and lactate dehydrogenase. J Nucl Med. 2020;61(5):689\u201395.","journal-title":"J Nucl Med"},{"issue":"1","key":"1151_CR89","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85\u201390.","journal-title":"J Nucl Med"},{"issue":"1","key":"1151_CR90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","volume":"17","author":"L Emmett","year":"2019","unstructured":"Emmett L, Crumbaker M, Ho B, et al. Results of a Prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin Genitourin Cancer. 2019;17(1):15\u201322.","journal-title":"Clin Genitourin Cancer"},{"issue":"Suppl. 7","key":"1151_CR91","doi-asserted-by":"publisher","first-page":"S1169","DOI":"10.1016\/j.annonc.2022.07.1504","volume":"33","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Sartor O, Saad F, et al. 1372P Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial. Ann Oncol. 2022;33(Suppl. 7):S1169\u201370.","journal-title":"Ann Oncol"},{"issue":"2","key":"1151_CR92","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, et al. Quantitative (68)Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following (177)Lu-PSMA-617 (VISION trial). Radiology. 2024;312(2): e233460.","journal-title":"Radiology"},{"issue":"Suppl. 16","key":"1151_CR93","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","volume":"40","author":"P Kuo","year":"2022","unstructured":"Kuo P, Hesterman J, Rahbar K, et al. [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy. J Clin Oncol. 2022;40(Suppl. 16):5002.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1151_CR94","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2967\/jnumed.121.263006","volume":"63","author":"QA Shagera","year":"2022","unstructured":"Shagera QA, Artigas C, Karfis I, et al. (68)Ga-PSMA PET\/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy. J Nucl Med. 2022;63(8):1191\u20138.","journal-title":"J Nucl Med"},{"issue":"12","key":"1151_CR95","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2967\/jnumed.121.263611","volume":"63","author":"CS Denis","year":"2022","unstructured":"Denis CS, Cousin F, Laere B, Hustinx R, Sautois BR, Withofs N. Using (68)Ga-PSMA-11 PET\/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: application of EAU\/EANM recommendations in clinical practice. J Nucl Med. 2022;63(12):1815\u201321.","journal-title":"J Nucl Med"},{"issue":"1","key":"1151_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/thno.37894","volume":"10","author":"RA Werner","year":"2020","unstructured":"Werner RA, Derlin T, Lapa C, et al. (18)F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10(1):1\u201316.","journal-title":"Theranostics."},{"issue":"7","key":"1151_CR97","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/RLU.0000000000001681","volume":"42","author":"JB Nielsen","year":"2017","unstructured":"Nielsen JB, Zacho HD, Haberkorn U, et al. A comprehensive safety evaluation of 68Ga-labeled ligand prostate-specific membrane antigen 11 PET\/CT in prostate cancer: the results of 2 prospective, multicenter trials. Clin Nucl Med. 2017;42(7):520\u20134.","journal-title":"Clin Nucl Med"},{"issue":"10","key":"1151_CR98","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2967\/jnumed.123.265750","volume":"64","author":"S Graves","year":"2023","unstructured":"Graves S. Radiation safety considerations of household waste disposal after release of patients who have received [177Lu]Lu-PSMA-617. J Nucl Med. 2023;64(10):1567.","journal-title":"J Nucl Med"},{"issue":"3","key":"1151_CR99","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.euo.2021.02.007","volume":"4","author":"SK Bhanvadia","year":"2021","unstructured":"Bhanvadia SK, Psutka SP, Burg ML, et al. Financial toxicity among patients with prostate, bladder, and kidney cancer: a systematic review and call to action. Eur Urol Oncol. 2021;4(3):396\u2013404.","journal-title":"Eur Urol Oncol."},{"issue":"7","key":"1151_CR100","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2967\/jnumed.121.264374","volume":"63","author":"J Czernin","year":"2022","unstructured":"Czernin J, Adams T, Calais J. More unacceptable denials: now it\u2019s PSMA-targeted PET\/CT imaging. J Nucl Med. 2022;63(7):969\u201370.","journal-title":"J Nucl Med"},{"issue":"5","key":"1151_CR101","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2967\/jnumed.120.251751","volume":"62","author":"MD Bucknor","year":"2021","unstructured":"Bucknor MD, Lichtensztajn DY, Lin TK, Borno HT, Gomez SL, Hope TA. Disparities in PET imaging for prostate cancer at a tertiary academic medical center. J Nucl Med. 2021;62(5):695\u20139.","journal-title":"J Nucl Med"},{"issue":"5","key":"1151_CR102","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2967\/jnumed.121.262332","volume":"62","author":"MD Bucknor","year":"2021","unstructured":"Bucknor MD, Hope TA. Reply: disparities in PET imaging of prostate cancer at a tertiary academic medical center. J Nucl Med. 2021;62(5):748.","journal-title":"J Nucl Med"},{"issue":"5","key":"1151_CR103","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2967\/jnumed.120.258160","volume":"62","author":"A Iagaru","year":"2021","unstructured":"Iagaru A, Franc B. Disparities in PET imaging of prostate cancer at a tertiary academic medical center. J Nucl Med. 2021;62(5):747\u20138.","journal-title":"J Nucl Med"},{"issue":"3","key":"1151_CR104","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2967\/jnumed.117.206953","volume":"59","author":"RJ Hicks","year":"2018","unstructured":"Hicks RJ. The injustice of being judged by the errors of others: the tragic tale of the battle for PET reimbursement. J Nucl Med. 2018;59(3):418\u201320.","journal-title":"J Nucl Med"},{"key":"1151_CR105","unstructured":"H.R.1199: Facilitating Innovative Nuclear Diagnostics Act of 2023. 2023. Available from: https:\/\/www.congress.gov\/bill\/118th-congress\/house-bill\/1199. Accessed Mar 2025."},{"key":"1151_CR106","unstructured":"S.1544: Facilitating Innovative Nuclear Diagnostics Act of 2023. 2024. Available from: https:\/\/www.congress.gov\/bill\/118th-congress\/senate-bill\/1544. Accessed Mar 2025."},{"key":"1151_CR107","unstructured":"Society of Nuclear Medicine and Molecular Imaging. In major win for patients, CMS adjusts nuclear medicine reimbursement policy, expanding access to life-saving scans. 2024. Available from: https:\/\/snmmi.org\/Web\/News\/Articles\/CMS-Adjusts-Nuclear-Medicine-Reimbursement-Policy--Expanding-Access-to-Life-Saving-Scans.aspx. Accessed Mar 2025."},{"issue":"1","key":"1151_CR108","doi-asserted-by":"publisher","DOI":"10.1097\/JU9.0000000000000003","volume":"1","author":"ED Crawford","year":"2023","unstructured":"Crawford ED, Albala DM, Harris RG, et al. A clinician\u2019s guide to targeted precision imaging in patients with prostate cancer (RADAR VI). JU Open Plus. 2023;1(1): e00003.","journal-title":"JU Open Plus."},{"issue":"3","key":"1151_CR109","doi-asserted-by":"publisher","DOI":"10.1097\/JU9.00000000000000011","volume":"1","author":"ED Crawford","year":"2023","unstructured":"Crawford ED, Harris RG, Slovin SF, et al. Synthesizing and applying molecular targeted imaging results in patients with prostate cancer (RADAR VII). JU Open Plus. 2023;1(3): e00011.","journal-title":"JU Open Plus."},{"key":"1151_CR110","doi-asserted-by":"publisher","first-page":"S1324","DOI":"10.1016\/j.annonc.2023.10.085","volume":"34","author":"O Sartor","year":"2023","unstructured":"Sartor O, Castellano Gauna DE, Herrmann K, et al. LBA13 phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). Ann Oncol. 2023;34:S1324\u20135.","journal-title":"Ann Oncol"},{"key":"1151_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102699","volume":"125","author":"EF Giunta","year":"2024","unstructured":"Giunta EF, Brighi N, Gurioli G, Matteucci F, Paganelli G, De Giorgi U. 177Lu-PSMA therapy in metastatic prostate cancer: an updated review of prognostic and predictive biomarkers. Cancer Treat Rev. 2024;125: 102699.","journal-title":"Cancer Treat Rev"},{"key":"1151_CR112","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1200\/JCO.2024.42.16_suppl.5016","volume":"42","author":"WP Fendler","year":"2024","unstructured":"Fendler WP, Karpinski J, H\u00fcsing J, et al. Prognostic PSMA-PET PROMISE nomograms for patients with prostate cancer. J Clin Oncol. 2024;42:5016.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 16","key":"1151_CR113","first-page":"abstract 8050","volume":"42","author":"J Panian","year":"2024","unstructured":"Panian J, Henderson N, Barata PC, et al. Association of tumor genetics with outcomes in patients (pts) with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617. J Clin Oncol. 2024;42(Suppl. 16):abstract 8050.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1151_CR114","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.2967\/jnumed.122.265242","volume":"64","author":"M Hotta","year":"2023","unstructured":"Hotta M, Gafita A, Murthy V, et al. PSMA PET tumor-to-salivary gland ratio to predict response to [(177)Lu]PSMA radioligand therapy: an international multicenter retrospective study. J Nucl Med. 2023;64(7):1024\u20139.","journal-title":"J Nucl Med"},{"key":"1151_CR115","unstructured":"ClinicalTrials.gov. 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for identification and treatment of PSMA-expressing metastatic castrate resistant prostate cancer (SECuRE) (SECuRE). NCT04868604. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04868604?tab=table. Accessed Mar 2025."},{"key":"1151_CR116","unstructured":"ClinicalTrials.gov. Study of diagnostic performance of [18F]CTT1057 for PSMA-positive tumors detection (GuideView). NCT04838626. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04838626?tab=table. Accessed Mar 2025."},{"key":"1151_CR117","unstructured":"ClinicalTrials.gov. Cu-64-PSMA-I&T positron emission tomography (PET) imaging of metastatic PSMA positive lesions in men with prostate cancer. NCT05653856. 2024. https:\/\/clinicaltrials.gov\/study\/NCT05653856?tab=table. Accessed Mar 2025."},{"key":"1151_CR118","unstructured":"ClinicalTrials.gov. F-18-PSMA-1007 versus F-18-fluorocholine PET in patients with biochemical recurrence. NCT04102553. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04102553?tab=table. Accessed Mar 2025."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01151-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01151-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01151-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:23:52Z","timestamp":1757183032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01151-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":118,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1151"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01151-7","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"28 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by SCELC, Statewide California Electronic Library Consortium.This article was funded by Novartis Pharmaceuticals Corporation. Medical writing and editorial support was provided by Greg Rowe, MSc, and Laura McArdle, BA, of Spark (a division of Prime, New York, NY, USA) and was funded by Novartis Pharmaceuticals Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Phillip H. Kuo received honoraria from Attralus, Blue Earth Diagnostics, dGenThera, Eli Lilly, General Electric Healthcare, Invicro, Novartis, and Telix Pharmaceuticals, research grants for his institution from Blue Earth Diagnostics and General Electric Healthcare, consulting fees from Attralus, Blue Earth Diagnostics, Chimerix, dGenThera, Eli Lilly, Fusion Pharma, General Electric Healthcare, Invicro, Life Molecular Imaging, Navidea, Novartis, Radionetics, Telix Pharmaceuticals, and United Imaging, support for attending meetings\/travel from Blue Earth Diagnostics, Eli Lilly, General Electric Healthcare, Invicro, Novartis, and Telix Pharmaceuticals, served on an advisory board for dGenThera, has a patent planned\/issued\/pending (Patent No. US 10,013,743 B2), received equipment\/materials\/drugs\/medical writing services\/gifts\/other services from Blue Earth Diagnostics, General Electric Healthcare, and Novartis, and holds a leadership\/fiduciary role at the Society of Nuclear Medicine and Molecular Imaging and the International Accreditation Council. Jeremie Calais received honoraria from Amgen, Astellas, Bayer, Blue Earth Diagnostics, Curium Pharma, DS Pharma, Fibrogen, GE Healthcare, Isoray, IBA RadioPharma, Janssen Pharmaceuticals, Lightpoint Medical, Lantheus\/Progenics\/EXINI, Monrol, Novartis\/Advanced Accelerator Applications, Pfizer, POINT Biopharma, Radiomedix, Sanofi, Siemens\/Varian, SOFIE, and Telix Pharmaceuticals\u00a0and research grants for his institution from Lantheus\/Progenics\/EXINI, Novartis\/Advanced Accelerator Applications, and POINT Biopharma. Mike Crosby received honoraria from Pfizer and Johnson & Johnson and served on an advisory board\/steering committee for Telix Pharmaceuticals, Novartis, and Johnson & Johnson.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data supporting the conclusion of this study have been included within the article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors discussed and conceived the idea for this article together. Literature searches and data analyses were performed by Spark, under the direction of Novartis Pharmaceuticals and the authors. All authors contributed to the drafting and critical review of this manuscript, and all authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}